[ad_1]
“Remdesivir is the first COVID-19 medicine recommended for use in the EU,” the agency said in a statement. However, it is noted that this recommendation has not yet been approved by the European Commission.
At least two studies in the United States have shown that remdesivir can reduce the length of hospitalization in patients with COVID-19 coronavirus infection.
The study findings, published in May in the prestigious New England Journal of Medicine, show that remdesivir injections, originally designed to treat Ebola fever, accelerated patients’ recovery compared to the placebo group alone.
The EEA Committee for Medicinal Products for Human Use (CHMP) has recommended that remdesivir receive conditional authorization for the treatment of adults and children infected with 12-year-old coronaviruses who have developed pneumonia and require supplemental oxygen.
It was previously reported that the cost of remdesivir treatment should be around $ 4,500 per COVID-19 patient, but in recent days it has become clear that a “competitor” has emerged, dexamethasone, which could drop to around $ 2,500-2,800.
[ad_2]
